Yüksek hizli IP adres arama için donanim mimarilerinin tasarimi ve gerçeklenmesi.

IP address lookup modules for backbone routers should store 100Ks of entries, find the longest prefix match (LPM) for each incoming packet at 10s of Gbps line speed and support thousands of lookup table updates each second. It is desired that these updates are non-blocking, that is without disrupting the ongoing lookups. Furthermore, considering the increasing line rates and table sizes, the scalability of the design is very important. The goal of this thesis is developing hardware IP lookup architectures that perform single clock cycle lookups and non-blocking updates that are entirely carried out on hardware. To this end, we propose a custom TCAM architecture for IP lookup that we call S-DIRECT-Scalable and Dynamically REConfigurable TCAM and a complete IP lookup solution that utilizes di_erent types of memory that we call SHIP-Scalable Highspeed IP lookup. Both S-DIRECT and SHIP feature a modular design that allows seamless scaling to di_erent table sizes. We implement the developed architectures on FPGA with a resource e_cient realization and provide the hardware requirements for implementation on other platforms. We demonstrate the viability of our architectures with a full implementation on FPGA that can store contemporary routing tables.Ph.D. - Doctoral Progra

S-DIRECT: Scalable and Dynamically Reconfigurable TCAM Architecture for High-Speed IP Lookup

IP address lookup modules for backbone routers should store 100Ks of entries, find the longest prefix match (LPM) for each incoming packet at 10s of Gbps line speed and support thousands of lookup table (LUT) updates each second. It is desired that these updates are non-blocking, that is without disrupting the ongoing lookups. Furthermore, considering the increasing line rates and table sizes, the scalability of the design is very important. Ternary content-addressable memory (TCAM) architectures are widely deployed for hardware IP lookup. In this paper, we propose a novel TCAM architecture, S-DIRECT-Scalable and Dynamically REConfigurable TCAM, that is custom designed for hardware IP lookup. S-DIRECT consists of hierarchically combined TCAM cells with inherent priority encoders (PEs) to support LPM. Hence, its design is scalable without any need for a separate PE or a redesign for different table size. Furthermore, S-DIRECT can perform constant time, non-blocking updates in hardware provided that certain write capabilities are present in the TCAM entries. S-DIRECT architecture is both independent of the hardware platform and the implementation of the TCAM cells. We demonstrate the generality and viability of S-DIRECT by implementing it both with prefix/mask register and LUT-based TCAM cells on FPGA

Clinical characteristics and therapeutic outcomes of elderly patients with chronic myeloid leukemia: A retrospective multicenter study

Aims: We aimed to investigate whether older age leads to limitations in the starting dose of imatinib in daily treatment of chronic myeloid leukemia, and to determine the compliance of elderly patients with tyrosine kinase inhibitors (TKI) therapy. Methods: Data including the clinical characteristics, therapeutic outcomes and compliance with TKI therapy of elderly patients with chronic myeloid leukemia aged >65years were collected from 13 institutions in Turkey, retrospectively. Results: A total of 69 patients (27 [39%] men, 42 [61%] women) were evaluated retrospectively. The median age of the patients was 71years (range 66-85years). Of the patients, 66 (96%) were in the chronic phase and three (4.3%) were in the accelerated phase when diagnosed. A total of 63 (91.3%) patients were receiving imatinib as the first-line therapy. The initial dose of imatinib was 400mg/day in 59 patients (93.6%). Imatinib treatment induced 57 (90.5%) complete hematological responses at 3months, 29 (46%) complete cytogenetic responses at 6months and 49 (77.7%) major molecular responses at 12months. As a result, nilotinib and dasatinib were used in 14 patients as second-line therapy. Second-line TKI induced nine complete hematological responses (64.3%) at 3months, four complete cytogenetic responses (28.6%) at 12months and seven major molecular responses (50%) at 18months. A total of 56 of the patients (81.2%) are still alive. The median overall survival and progression-free survival rates were 35months (range 1-95months) and 17months (range 0.8-95months), respectively. Conclusion: Elderly patients should receive TKI according to the same guidelines that apply to younger patients. © 2014 Japan Geriatrics Society

with chronic myeloid leukemia: A retrospective multicenter study

AimsWe aimed to investigate whether older age leads to limitations in the starting dose of imatinib in daily treatment of chronic myeloid leukemia, and to determine the compliance of elderly patients with tyrosine kinase inhibitors (TKI) therapy.MethodsData including the clinical characteristics, therapeutic outcomes and compliance with TKI therapy of elderly patients with chronic myeloid leukemia aged >65years were collected from 13 institutions in Turkey, retrospectively.ResultsA total of 69 patients (27 [39%] men, 42 [61%] women) were evaluated retrospectively. The median age of the patients was 71years (range 66-85years). Of the patients, 66 (96%) were in the chronic phase and three (4.3%) were in the accelerated phase when diagnosed. A total of 63 (91.3%) patients were receiving imatinib as the first-line therapy. The initial dose of imatinib was 400mg/day in 59 patients (93.6%). Imatinib treatment induced 57 (90.5%) complete hematological responses at 3months, 29 (46%) complete cytogenetic responses at 6months and 49 (77.7%) major molecular responses at 12months. As a result, nilotinib and dasatinib were used in 14 patients as second-line therapy. Second-line TKI induced nine complete hematological responses (64.3%) at 3months, four complete cytogenetic responses (28.6%) at 12months and seven major molecular responses (50%) at 18months. A total of 56 of the patients (81.2%) are still alive. The median overall survival and progression-free survival rates were 35months (range 1-95months) and 17months (range 0.8-95months), respectively.ConclusionElderly patients should receive TKI according to the same guidelines that apply to younger patients. Geriatr Gerontol Int 2015; 15: 729-735